Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TYLENOL W/ CODEINE vs HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Codeine is a prodrug that is metabolized to morphine, which acts as a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways.
Hydrocodone is a semisynthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Homatropine methylbromide is an anticholinergic agent that reduces gastrointestinal motility and secretions.
Mild to moderate pain,Pain not relieved by non-opioid analgesics alone
Management of moderate to moderately severe pain where an antitussive effect is desired (hydrocodone component),Off-label: symptomatic relief of irritable bowel syndrome (homatropine methylbromide anticholinergic effect)
1-2 tablets (300-600 mg acetaminophen / 30-60 mg codeine) every 4-6 hours as needed; maximum 12 tablets/day (codeine max 360 mg, acetaminophen max 3600 mg). Route: oral.
Oral: 5 mg hydrocodone/1.5 mg homatropine every 4 to 6 hours as needed; maximum 30 mg hydrocodone per day.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Codeine: 2.5-4 hours (slower in CYP2D6 poor metabolizers).
The terminal elimination half-life of hydrocodone is approximately 3.8-4.5 hours in adults, though it may be prolonged in hepatic impairment or elderly patients. Homatropine methylbromide has a half-life of about 2-3 hours.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: extend interval to 6-8 hours; avoid if GFR < 10 m L/min.
GFR 30-89 m L/min: No adjustment. GFR 10-29 m L/min: Reduce dose by 25-50% or extend interval. GFR <10 m L/min: Reduce dose by 50% or extend interval to every 8-12 hours.
Risk of respiratory depression, addiction, abuse, and misuse; life-threatening respiratory depression can occur; accidental ingestion can be fatal; risks from concomitant use with benzodiazepines or other CNS depressants; neonatal opioid withdrawal syndrome with prolonged use; ultra-rapid metabolizers of codeine can convert to morphine faster, leading to fatal respiratory depression.
FDA Pregnancy Category C prior to 2015; current data insufficient to rule out risk. First trimester: association with oral clefts in some studies, but confounding by maternal condition. Second/third trimester: respiratory depression in neonate if used near term; chronic use may lead to neonatal opioid withdrawal syndrome. Avoid prolonged use or high doses.
First trimester: Limited data; hydrocodone is not a major teratogen but opioid use may be associated with neural tube defects (RR 1.5-2.0) based on some studies. Homatropine methylbromide: No adequate studies; anticholinergics may be associated with minor malformations. Second trimester: No specific structural risks identified. Third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS); anticholinergic effects may cause neonatal ileus or urinary retention.
Tylenol with Codeine contains acetaminophen 300 mg and codeine 30 mg per tablet. Codeine is a prodrug metabolized by CYP2D6 to morphine; poor metabolizers (7-10% of population) may have reduced analgesia, while ultra-rapid metabolizers risk toxicity. Maximum acetaminophen dose is 4 g/day; hepatotoxicity risk with alcohol use. Avoid in children under 12 years due to risk of respiratory depression; FDA boxed warning for children post-tonsillectomy/adenoidectomy. Constipation common; prescribe stool softeners proactively.
Hydrocodone bitartrate is an opioid agonist; homatropine methylbromide is an anticholinergic. The combination is used for cough suppression. Caution in patients with respiratory depression, COPD, or asthma. Monitor for CNS depression and constipation. The anticholinergic component may cause dry mouth, urinary retention, and blurred vision. Avoid use in patients with narrow-angle glaucoma or gastrointestinal obstruction. The recommended dose is one tablet every 4-6 hours; do not exceed 6 tablets per day. Use with caution in elderly or debilitated patients. Abrupt discontinuation may cause withdrawal symptoms.
No interactions on record
No interactions on record
Common clinical questions about TYLENOL W/ CODEINE vs HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, answered by our medical review team.
TYLENOL W/ CODEINE is a Opioid Agonist that works by Codeine is a prodrug that is metabolized to morphine, which acts as a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways.. HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE is a Opioid Agonist that works by Hydrocodone is a semisynthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Homatropine methylbromide is an anticholinergic agent that reduces gastrointestinal motility and secretions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TYLENOL W/ CODEINE and HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TYLENOL W/ CODEINE is: 1-2 tablets (300-600 mg acetaminophen / 30-60 mg codeine) every 4-6 hours as needed; maximum 12 tablets/day (codeine max 360 mg, acetaminophen max 3600 mg). Route: oral.. The standard adult dose of HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE is: Oral: 5 mg hydrocodone/1.5 mg homatropine every 4 to 6 hours as needed; maximum 30 mg hydrocodone per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TYLENOL W/ CODEINE and HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TYLENOL W/ CODEINE is classified as Category D/X. FDA Pregnancy Category C prior to 2015; current data insufficient to rule out risk. First trimester: association with oral clefts in some studies, but confounding by maternal condi. HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE is classified as Category D/X. First trimester: Limited data; hydrocodone is not a major teratogen but opioid use may be associated with neural tube defects (RR 1.5-2.0) based on some studies. Homatropine methyl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Acetaminophen is primarily metabolized via glucuronidation and sulfation; codeine is metabolized via CYP2D6 to morphine, CYP3A4 to norcodeine, and glucuronidation.
Hydrocodone: primarily hepatic via CYP2D6 and CYP3A4 to hydromorphone, norhydrocodone, and other metabolites. Homatropine methylbromide: poorly absorbed; metabolized via ester hydrolysis and renal excretion.
Renal: ~90% as glucuronide conjugates (acetaminophen 50-70%, codeine 10-15%), 10-15% as free acetaminophen, <5% free codeine; biliary/fecal: <5%.
Hydrocodone and its metabolites are primarily excreted renally. Approximately 60% of a dose is eliminated in urine as unchanged drug and conjugates, with less than 5% excreted in feces. Homatropine methylbromide is a quaternary ammonium compound that is poorly absorbed and excreted mainly unchanged in feces via biliary elimination.
Acetaminophen: 10-25% (albumin). Codeine: 7-25% (albumin).
Hydrocodone is approximately 20-30% bound to plasma proteins, primarily albumin. Homatropine methylbromide has negligible protein binding (<5%).
Acetaminophen: 0.8-1.0 L/kg (distributes evenly in body water). Codeine: 3-6 L/kg (extensive tissue distribution).
The volume of distribution for hydrocodone is approximately 3.3-4.7 L/kg, indicating extensive tissue distribution. For homatropine methylbromide, Vd is roughly 0.5-1 L/kg due to its quaternary structure limiting CNS penetration.
Oral: acetaminophen: 85-98%; codeine: ~90% (first-pass metabolism to morphine via CYP2D6 reduces systemic bioavailability of active metabolite).
Hydrocodone has an oral bioavailability of approximately 50-60% due to first-pass metabolism. Homatropine methylbromide is poorly absorbed orally, with bioavailability less than 10%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use or use with extreme caution with 75% dose reduction.
Based on codeine component: 0.5-1 mg codeine/kg/dose every 4-6 hours. Note: codeine contraindicated in children <12 years due to FDA boxed warning.
Children ≥6 years: 2.5 mg hydrocodone/0.75 mg homatropine orally every 4-6 hours as needed; maximum 15 mg hydrocodone per day. Children <6 years: Not recommended.
Start at lower end of dosing (e.g., 1 tablet every 6 hours); monitor for respiratory depression and CNS effects; consider reducing acetaminophen max if hepatic impairment.
Initiate at lowest effective dose (e.g., 2.5 mg hydrocodone/0.75 mg homatropine every 6 hours) with careful titration due to increased risk of falls, respiratory depression, and anticholinergic effects.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants.
Respiratory depression, drug dependence, interactions with CNS depressants, hepatotoxicity from acetaminophen, ultra-rapid metabolizer risk, elderly or debilitated patients, renal impairment, head injury, acute abdominal conditions.
Respiratory depression, especially in elderly or debilitated; CNS depression; risk of opioid-induced hyperalgesia; increased intracranial pressure; severe hypotension; anticholinergic effects (constipation, urinary retention, blurred vision); tolerance and dependence; interactions with alcohol and other CNS depressants.
Hypersensitivity to acetaminophen or codeine, significant respiratory depression, acute or severe bronchial asthma, gastrointestinal obstruction, use of MAO inhibitors within 14 days, post-operative pain in children after tonsillectomy/adenoidectomy.
Hypersensitivity to hydrocodone, homatropine, or any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; paralytic ileus; suspected surgical abdomen; narrow-angle glaucoma; urinary retention; concurrent use of MAOIs within 14 days.
Avoid alcohol due to increased hepatotoxicity risk and CNS depression. High-fat meals may delay absorption but not significantly alter clinical effect. No specific food restrictions otherwise.
Avoid grapefruit and grapefruit juice as they may increase hydrocodone levels. Avoid alcohol as it enhances CNS depression. No other significant food interactions.
Codeine is excreted into breast milk. M/P ratio approximately 2.1 (codeine and metabolites). Low levels generally considered compatible with breastfeeding; but ultra-rapid metabolizers may transfer higher morphine levels. Monitor infant for sedation, respiratory depression, poor feeding. American Academy of Pediatrics recommends caution.
Hydrocodone is excreted into breast milk (M/P ratio approximately 2.0-2.5 based on a single study). Relative infant dose estimated at 2-4% of maternal weight-adjusted dose. Homatropine methylbromide: Quaternary ammonium compound; expected minimal excretion but no data. American Academy of Pediatrics considers hydrocodone compatible with breastfeeding, but monitor infant for drowsiness, respiratory depression, and constipation. Avoid use in mothers with CYP2D6 ultra-rapid metabolizer phenotype due to increased morphine production.
No standard dose adjustment required; however, pregnancy may increase clearance of codeine due to enhanced hepatic metabolism and increased renal blood flow, potentially requiring higher doses for efficacy. Use lowest effective dose for shortest duration. Avoid in prolonged labor due to risk of respiratory depression in neonate.
No specific pharmacokinetic studies in pregnancy for this combination. In pregnancy, increased plasma volume and renal clearance may reduce hydrocodone concentrations, potentially requiring dose increases for adequate analgesia. However, due to risk of neonatal withdrawal, use lowest effective dose for shortest duration. Homatropine methylbromide: No dose adjustment data; use cautiously due to potential for anticholinergic side effects.
Do not exceed 12 tablets in 24 hours due to acetaminophen content; liver damage risk with overdose.,Avoid alcohol while taking this medication.,May cause drowsiness; do not drive or operate machinery until you know how you react.,Take with food to reduce nausea.,Do not take with other products containing acetaminophen (e.g., Tylenol, cold medications).,Report signs of allergic reaction (rash, itching) or breathing difficulties immediately.,Codeine can be habit-forming; use only as prescribed.
Take exactly as prescribed. Do not take more than recommended.,Avoid alcohol or other sedatives while taking this medication.,May cause drowsiness or dizziness. Do not drive or operate machinery until you know how it affects you.,Report difficulty breathing, severe constipation, or urinary retention.,May be habit forming. Do not share with others.,Store safely away from children and pets.,Do not stop abruptly without consulting your doctor.